drugset / Trial / NCT01756508

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

NCT01756508

Phase 2 Completed 57 enrolled Russian Academy of Medical Sciences
RandomizedParallel-groupOpen-labelPrevention

Summary

Study of eculizumab ability to correct the reperfusion injury of the kidney allograft.

Timeline

Start
2012-09-01
Primary completion
2017-04-15
Completion
2017-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody 1200 mg/m2